PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study - The Lancet

JCM, Free Full-Text

Muscle- and skeletal-related side-effects of statins: tip of the iceberg? - Johann Auer, Helmut Sinzinger, Barry Franklin, Robert Berent, 2016

bok%3A978-1-4939-0515-7.pdf ?auth66=1397940469_51b8ba57efa3ddcad3f8aa303951bc25&ext=

Chapters Archive - Endotext

Endocrine and toxic myopathies (Chapter 24) - Disorders of Voluntary Muscle

PDF) Statin-induced myopathy: A review and update

PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

2018 Guidelines for the management of dyslipidemia

PDF] Statin myopathy: A common dilemma not reflected in clinical trials

Safety monitoring of drug-induced muscle injury and rhabdomyolysis: a biomarker-guided approach for clinical practice and drug trials

Impact of critical illness on cholesterol and fatty acids: insights into pathophysiology and therapeutic targets, Intensive Care Medicine Experimental

JCM, Free Full-Text

Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal - ScienceDirect